Literature DB >> 8498513

Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats.

S S Lee1, K A Sharkey.   

Abstract

To investigate a possible role of primary afferent innervation in the pathogenesis of hyperkinetic circulation in cirrhosis or portal hypertension, we used capsaicin to denervate the primary afferent nerves. Rat pups were injected with capsaicin (50 mg/kg) or a vehicle and were allowed to grow. When they reached young adulthood, operations to induce portal hypertension by portal vein stenosis or cirrhosis by bile duct ligation were performed. A control group had sham operation. Cardiac output and regional blood flows were measured in unrestrained conscious rats by radioactive microspheres. Capsaicin-treated portal hypertensive and cirrhotic rats had cardiac output and systemic vascular resistance similar to sham-operated rats, whereas the vehicle-treated portal hypertensive and cirrhotic rats showed the hyperkinetic circulation. No hemodynamic effect of capsaicin on sham-operated rats was detected. Capsaicin-treated rats did not demonstrate a splanchnic or renal hyperemia, but the percentage of cardiac output in these vascular beds was similar to controls. These results suggest that capsaicin treatment blocked the generalized vasodilatation in cirrhotic and portal hypertensive rats. Arterial pressure and heart rate were not modified in any group. These results show that denervation of capsaicin-sensitive primary afferent nerves in cirrhotic and portal hypertensive rats blocked the expected development of hyperkinetic circulation. We conclude that primary afferent innervation may be important in the genesis of hyperdynamic circulation in portal hypertension and cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498513     DOI: 10.1152/ajpgi.1993.264.5.G868

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

2.  Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

Authors:  L Moezi; S A Gaskari; H Liu; S K Baik; A R Dehpour; S S Lee
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

3.  Temporal expression of hepatic inducible nitric oxide synthase in liver cirrhosis.

Authors:  Chang-Li Wei; Wei-Min Hon; Kang-Hoe Lee; Hoon-Eng Khoo
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 4.  Cardiac and vascular changes in cirrhosis: pathogenic mechanisms.

Authors:  HongQun Liu; Seyed Ali Gaskari; Samuel S Lee
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

5.  Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle.

Authors:  J M Pak; A S Adeagbo; C R Triggle; E A Shaffer; S S Lee
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

6.  Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats.

Authors:  Y Li; D Song; Y Zhang; S S Lee
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 7.  Pathogenesis of portal hypertensive gastropathy: translating basic research into clinical practice.

Authors:  Rafael F Perini; Paula R S Camara; Jose G P Ferraz
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-02-03

Review 8.  Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.

Authors:  Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

9.  Inhibition of neuronal apoptosis and axonal regression ameliorates sympathetic atrophy and hemodynamic alterations in portal hypertensive rats.

Authors:  Nahia Ezkurdia; Imma Raurell; Sarai Rodríguez; Antonio González; Rafael Esteban; Joan Genescà; María Martell
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.